{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:16:11Z","timestamp":1794539771697,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16060-9","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:46:27Z","timestamp":1777005987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Population-specific MicroRNA biomarker discovery in breast ductal carcinoma via explainable graph neural multi-omics modeling"],"prefix":"10.1186","volume":"26","author":[{"given":"Elham Saleh","family":"Albalawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibran","family":"Qayyum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaid","family":"Qayyum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"16060_CR1","doi-asserted-by":"publisher","unstructured":"Fasoulakis Z, Psarommati MZ, Papapanagiotou A, Pergialiotis V, Koutras A, Douligeris A, Mortaki A, Mihail A, Theodora M, Stavros S, Karakalpakis D, Papamihail M, Kontomanolis EN, Daskalakis G, Antsaklis P. MicroRNAs Can Influence Ovarian Cancer Progression by Dysregulating Integrin Activity. Cancers. 2023;15(18):4449. https:\/\/doi.org\/10.3390\/cancers15184449Activity","DOI":"10.3390\/cancers15184449Activity"},{"issue":"6","key":"16060_CR2","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.7150\/jca.39044","volume":"11","author":"D Cao","year":"2020","unstructured":"Cao D, Di M, Liang J, Shi S, Tan Q, Wang Z. MicroRNA-183 in cancer progression. J Cancer. 2020;11(6):1315\u201324. https:\/\/doi.org\/10.7150\/jca.39044.","journal-title":"J Cancer"},{"issue":"19","key":"16060_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20194940","volume":"20","author":"HY Loh","year":"2019","unstructured":"Loh HY, Norman BP, Lai KS, Rahman NMANA, Alitheen NBM, Osman MA. The regulatory role of microRNAs in breast cancer. Int J Mol Sci. 2019;20(19):1\u201327. https:\/\/doi.org\/10.3390\/ijms20194940.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"16060_CR4","doi-asserted-by":"publisher","first-page":"7095","DOI":"10.1007\/s13277-016-5017-y","volume":"37","author":"J Chen","year":"2016","unstructured":"Chen J, Zhang K, Xu Y, Gao Y, Li C, Wang R, et al. The role of microRNA-26a in human cancer progression and clinical application. Tumor Biol. 2016;37(6):7095\u2013108. https:\/\/doi.org\/10.1007\/s13277-016-5017-y.","journal-title":"Tumor Biol"},{"issue":"23","key":"16060_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14235748","volume":"14","author":"LA de Rooij","year":"2022","unstructured":"de Rooij LA, Mastebroek DJ, ten Voorde N, van der Wall E, van Diest PJ, Moelans CB. The microRNA lifecycle in health and cancer. Cancers Basel. 2022;14(23):1\u201336. https:\/\/doi.org\/10.3390\/cancers14235748.","journal-title":"Cancers Basel"},{"key":"16060_CR6","doi-asserted-by":"publisher","unstructured":"Elayapillai SP, Dogra S, Hladik C, Lausen J, Bruns M, Gossett AG, Behbod F, Xu C, Zhang R, Ding WQ, Hannafon BN. Preferential release of microRNAs via extracellular vesicles is associated with ductal carcinoma in situ to invasive breast cancer progression. Cancer Lett. 2025;217794. https:\/\/doi.org\/10.1016\/j.canlet.2025.217794.","DOI":"10.1016\/j.canlet.2025.217794"},{"issue":"11","key":"16060_CR7","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.3390\/ijms26115380","volume":"26","author":"G D\u2019Amico","year":"2025","unstructured":"D\u2019Amico G, Starace R, Della Lastra M, Marimpietri D, Dander E, Morandi F, et al. Dysregulation of the bone marrow microenvironment in pediatric tumors: the role of extracellular vesicles in acute leukemias and neuroblastoma. Int J Mol Sci. 2025;26(11):5380. https:\/\/doi.org\/10.3390\/ijms26115380.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"16060_CR8","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.3390\/cancers17162618","volume":"17","author":"A Bam","year":"2025","unstructured":"Bam A, Hu Y, Wu X, Luo M, Rizvi N, Del Valle L, et al. Differential miRNA expressions linking environmental risk factors to triple-negative breast cancer stages at diagnosis. Cancers. 2025;17(16):2618. https:\/\/doi.org\/10.3390\/cancers17162618.","journal-title":"Cancers"},{"issue":"1","key":"16060_CR9","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.3390\/cancers17162640","volume":"15","author":"E Ali","year":"2025","unstructured":"Ali E, Ahmed MA, Shawki MA, El Arab LRE, Khalifa MK, Swellam M. Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma. Sci Rep. 2025;15(1):1933. https:\/\/doi.org\/10.3390\/cancers17162640.","journal-title":"Sci Rep"},{"issue":"4","key":"16060_CR10","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.62347\/AMTI5713","volume":"15","author":"H Liu","year":"2025","unstructured":"Liu H, Li X, Wang G, Ren Y, Fan Z, Tang X. Circ_0000190 inhibits the progression of triple-negative breast cancer by regulating miR-301a\/MEOX2 pathway. Am J Cancer Res. 2025;15(4):1559. https:\/\/doi.org\/10.62347\/AMTI5713.","journal-title":"Am J Cancer Res"},{"issue":"6","key":"16060_CR11","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3322\/caac.21583","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Sauer AG, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438\u201351. https:\/\/doi.org\/10.3322\/caac.21583.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"16060_CR12","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.21037\/qims-2025-434","volume":"15","author":"J Huang","year":"2025","unstructured":"Huang J, Lin Q. Correlation between multimodality imaging features and molecular subtypes in breast cancer: a comparative study between young (\u2264 30 years) and middle-aged (45\u201355 years) women. Quant Imaging Med Surg. 2025;15(8):7537. https:\/\/doi.org\/10.21037\/qims-2025-434.","journal-title":"Quant Imaging Med Surg"},{"key":"16060_CR13","doi-asserted-by":"publisher","unstructured":"Valdez I, Pramanik P. Exploring the interplay of adiposity, ethnicity, and hormone receptor profiles in breast cancer subtypes. arXiv preprint arXiv:2507.21348. 2025. https:\/\/doi.org\/10.48550\/arXiv.2507.21348.","DOI":"10.48550\/arXiv.2507.21348"},{"key":"16060_CR14","doi-asserted-by":"publisher","unstructured":"Tseng YA, Tamayo S, Abada E, Marketkar S, Hanley LC, Hansen K, Quddus MR, Sung CJ, Singh K. Interobserver agreement in scoring HER2-negative and HER2-low immunohistochemistry in breast cancer: reasons for discordance and impact of a single training session. Am J Clin Pathol. 2025:aqaf043. https:\/\/doi.org\/10.1093\/ajcp\/aqaf043.","DOI":"10.1093\/ajcp\/aqaf043"},{"issue":"1","key":"16060_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43094-025-00869-5","volume":"11","author":"Y Elsherif","year":"2025","unstructured":"Elsherif Y, Rady M, Abdelaziz H, El-Azizi M. Expression profiling of T cell and B cell activation genes and immunoglobulin G subclasses in Egyptian breast cancer patients. Future J Pharm Sci. 2025;11(1):1\u201314. https:\/\/doi.org\/10.1186\/s43094-025-00869-5.","journal-title":"Future J Pharm Sci"},{"issue":"1","key":"16060_CR16","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.clbc.2024.06.013","volume":"25","author":"AX Chen","year":"2025","unstructured":"Chen AX, Chen X, Li XX, Guo ZY, Cao XC, Wang X, et al. Impacts of tumor stage at diagnosis and adjuvant therapy on long-term survival outcomes in patients with triple-negative breast cancer achieving pathologic complete response after neoadjuvant chemotherapy. Clin Breast Cancer. 2025;25(1):e30\u20139. https:\/\/doi.org\/10.1016\/j.clbc.2024.06.013.","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"16060_CR17","doi-asserted-by":"publisher","first-page":"pkaf022","DOI":"10.1093\/jncics\/pkaf022","volume":"9","author":"T Yoshino","year":"2025","unstructured":"Yoshino T, Zhang Z, Sato R, Lipkowitz S, Fujii T. Revisiting surrogacy of pathological complete response for long-term survival in triple-negative breast cancer. JNCI Cancer Spectr. 2025;9(2):pkaf022. https:\/\/doi.org\/10.1093\/jncics\/pkaf022.","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"16060_CR18","doi-asserted-by":"publisher","first-page":"e25126","DOI":"10.1002\/jcla.25126","volume":"39","author":"W Xu","year":"2025","unstructured":"Xu W, Yuan F. Detection of circulating tumor cells in the prognostic significance of patients with breast cancer: a retrospective study. J Clin Lab Anal. 2025;39(1):e25126. https:\/\/doi.org\/10.1002\/jcla.25126.","journal-title":"J Clin Lab Anal"},{"issue":"3","key":"16060_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000530584","volume":"18","author":"M Balic","year":"2023","unstructured":"Balic M, Thomssen C, Gnant M, Harbeck N. St. Gallen\/Vienna 2023: Optimization of treatment for patients with primary breast cancer \u2013 A brief summary of the consensus discussion. Breast Care (Basel). 2023;18(3):213\u201322. https:\/\/doi.org\/10.1159\/000530584.","journal-title":"Breast Care (Basel)"},{"issue":"9","key":"16060_CR20","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3390\/cancers17091482","volume":"17","author":"S Mar\u00edn-Li\u00e9bana","year":"2025","unstructured":"Mar\u00edn-Li\u00e9bana S, Llor P, Serrano-Garc\u00eda L, Fern\u00e1ndez-Murga ML, Comes-Raga A, Torregrosa D, et al. Gene expression signatures for guiding initial therapy in ER+\/HER2-early breast cancer. Cancers Basel. 2025;17(9):1482. https:\/\/doi.org\/10.3390\/cancers17091482.","journal-title":"Cancers Basel"},{"issue":"4","key":"16060_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.5858\/arpa.2022-0070-RA","volume":"18","author":"M Roy","year":"2023","unstructured":"Roy M, Fowler AM, Ulaner GA, Mahajan A. Molecular classification of breast cancer. PET Clin. 2023;18(4):441\u201358. https:\/\/doi.org\/10.5858\/arpa.2022-0070-RA.","journal-title":"PET Clin"},{"issue":"4","key":"16060_CR22","doi-asserted-by":"publisher","first-page":"e70008","DOI":"10.1002\/cncy.70008","volume":"133","author":"MH Maher","year":"2025","unstructured":"Maher MH, Treekitkarnmongkol W, Ghatak S, Dai J, Liu S, Nguyen T, et al. An integrated multi-omics biomarker approach using molecular profiling and microRNAs for evaluation of pancreatic cyst fluid. Cancer Cytopathol. 2025;133(4):e70008. https:\/\/doi.org\/10.1002\/cncy.70008.","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"16060_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12672-025-02064-7","volume":"16","author":"EU Alum","year":"2025","unstructured":"Alum EU. AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis. Discov Oncol. 2025;16(1):1\u201312. https:\/\/doi.org\/10.1007\/s12672-025-02064-7.","journal-title":"Discov Oncol"},{"key":"16060_CR24","doi-asserted-by":"publisher","unstructured":"Chakraborty SS, Ray Dutta J, Ganesan R, Minary P. The evolution of nucleic acid\u2013based diagnosis methods from the (pre-) CRISPR to CRISPR era and the associated machine\/deep learning approaches in relevant RNA design. In RNA Design: Methods and Protocols. Springer US; 2024. pp. 241-300. https:\/\/doi.org\/10.1007\/978-1-0716-4079-1_17.","DOI":"10.1007\/978-1-0716-4079-1_17"},{"key":"16060_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ncrna.2024.12.002","volume":"11","author":"A Sufianov","year":"2025","unstructured":"Sufianov A, Agaverdiev M, Mashkin A, Ilyasova T. Targeting microRNA methylation: innovative approaches to diagnosing and treating hepatocellular carcinoma. Non-coding RNA Res. 2025;11:150\u20137. https:\/\/doi.org\/10.1016\/j.ncrna.2024.12.002.","journal-title":"Non-coding RNA Res"},{"key":"16060_CR26","doi-asserted-by":"publisher","first-page":"1591119","DOI":"10.3389\/fmedt.2025.1591119","volume":"7","author":"K Amoako","year":"2025","unstructured":"Amoako K, Mokhammad A, Malik A, Yesudasan S, Wheba A, Olagunju O, et al. Enhancing nucleic acid delivery by the integration of artificial intelligence into lipid nanoparticle formulation. Front Med Technol. 2025;7:1591119. https:\/\/doi.org\/10.3389\/fmedt.2025.1591119.","journal-title":"Front Med Technol"},{"key":"16060_CR27","doi-asserted-by":"publisher","unstructured":"Wu MY, Hu PW, You ZH, Zhang J, Hu L, Luo X. Graph-based prediction of miRNA-drug associations with multisource information and metapath enhancement matrices. IEEE J Biomed Health Informatics. 2025. https:\/\/doi.org\/10.1109\/JBHI.2025.3558303.","DOI":"10.1109\/JBHI.2025.3558303"},{"issue":"April","key":"16060_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmolb.2023.1162463","volume":"10","author":"Y Fu","year":"2023","unstructured":"Fu Y, Yang Q, Yang H, Zhang X. New progress in the role of microRNAs in the diagnosis and prognosis of triple-negative breast cancer. Front Mol Biosci. 2023;10(April):1\u201312. https:\/\/doi.org\/10.3389\/fmolb.2023.1162463.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"16060_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10549-019-05192-1","volume":"176","author":"J Lee","year":"2019","unstructured":"Lee J, Kim HE, Song YS, Cho EY, Lee A. miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway. Breast Cancer Res Treat. 2019;176(1):119\u201330. https:\/\/doi.org\/10.1007\/s10549-019-05192-1.","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"16060_CR30","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.febslet.2010.08.009","volume":"585","author":"SA Melo","year":"2011","unstructured":"Melo SA, Esteller M. Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett. 2011;585(13):2087\u201399. https:\/\/doi.org\/10.1016\/j.febslet.2010.08.009.","journal-title":"FEBS Lett"},{"issue":"9","key":"16060_CR31","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.21037\/tcr-20-1294","volume":"9","author":"PC Sharma","year":"2020","unstructured":"Sharma PC, Gupta A. MicroRNAs: potential biomarkers for diagnosis and prognosis of different cancers. Transl Cancer Res. 2020;9(9):5798\u2013818. https:\/\/doi.org\/10.21037\/tcr-20-1294.","journal-title":"Transl Cancer Res"},{"issue":"3","key":"16060_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"F Bray","year":"2021","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"16060_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2022.09.010","volume":"176","author":"KR Chadda","year":"2022","unstructured":"Chadda KR, Blakey EE, Coleman N, Murray MJ. The clinical utility of dysregulated microRNA expression in paediatric solid tumors. Eur J Cancer. 2022;176:133\u201354. https:\/\/doi.org\/10.1016\/j.ejca.2022.09.010.","journal-title":"Eur J Cancer"},{"key":"16060_CR34","doi-asserted-by":"publisher","unstructured":"Hajibabaei S, Sotoodehnejadnematalahi F, Nafissi N, Zeinali S, Azizi M. Aberrant promoter hypermethylation of miR-335 and miR-145 is involved in breast cancer PD-L1 overexpression. Sci Rep. 2023;13(1). https:\/\/doi.org\/10.1038\/s41598-023-27415-8.","DOI":"10.1038\/s41598-023-27415-8"},{"issue":"3","key":"16060_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/PPO.0b013e318250c001","volume":"18","author":"MV Iorio","year":"2012","unstructured":"Iorio MV, Croce CM. Causes and consequences of MicroRNA dysregulation. Cancer J (United States). 2012;18(3):215\u201322. https:\/\/doi.org\/10.1097\/PPO.0b013e318250c001.","journal-title":"Cancer J (United States)"},{"issue":"2","key":"16060_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.pulmoe.2021.05.005","volume":"29","author":"T Jia","year":"2023","unstructured":"Jia T, Zhang Q, Xu H, Liu H, Gu X. The function of miR-637 in non-small cell lung cancer progression and prognosis. Pulmonology. 2023;29(2):111\u20138. https:\/\/doi.org\/10.1016\/j.pulmoe.2021.05.005.","journal-title":"Pulmonology"},{"issue":"20","key":"16060_CR37","doi-asserted-by":"publisher","first-page":"12541","DOI":"10.3390\/ijms232012541","volume":"23","author":"SA Karimi","year":"2022","unstructured":"Karimi SA, Rahimi S, Nejadi N. Liquid biopsy approaches in cancer: emerging roles of circulating microRNAs and tumor DNA. Int J Mol Sci. 2022;23(20):12541. https:\/\/doi.org\/10.3390\/ijms232012541.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"16060_CR38","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.31557\/APJCP.2022.23.10.3361","volume":"23","author":"NS Kandil","year":"2022","unstructured":"Kandil NS, Kandil LS, Mohamed R, Selima M, El Nemr M, Barakat AR, et al. The role of miRNA-182 and FOXO3 expression in breast cancer. Asian Pac J Cancer Prev. 2022;23(10):3361\u201370. https:\/\/doi.org\/10.31557\/APJCP.2022.23.10.3361.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"16060_CR39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4048\/jbc.2019.22.e4","volume":"22","author":"S Li","year":"2019","unstructured":"Li S, Pu T, Xiao L, Gao H, Li L, Ye F, et al. Screening of recurrence related microRNA in ductal carcinoma in situ and functional study of microRNA-654-5p. J Breast Cancer. 2019;22(1):52\u201366. https:\/\/doi.org\/10.4048\/jbc.2019.22.e4.","journal-title":"J Breast Cancer"},{"issue":"2","key":"16060_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.31031\/nacs.2020.04.000582","volume":"4","author":"Y Lu","year":"2020","unstructured":"Lu Y. The role of microRNAs in the progression, prognostication, and treatment of breast cancer. Novel Approaches Cancer Study. 2020;4(2):337\u201346. https:\/\/doi.org\/10.31031\/nacs.2020.04.000582.","journal-title":"Novel Approaches Cancer Study"},{"issue":"3","key":"16060_CR41","doi-asserted-by":"publisher","first-page":"101573","DOI":"10.1016\/j.esmoop.2023.101573","volume":"8","author":"A Natalicchio","year":"2023","unstructured":"Natalicchio A, Montagnani M, Gallo M, Marrano N, Faggiano A, Zatelli MC, et al. MiRNA dysregulation underlying common pathways in type 2 diabetes and cancer development: an Italian Association of Medical Oncology (AIOM)\/Italian Association of Medical Diabetologists (AMD)\/Italian Society of Diabetology (SID)\/Italian Society of Endocrinology (SIE)\/Italian Society of Pharmacology (SIF) multidisciplinary critical view. ESMO Open. 2023;8(3):101573. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101573.","journal-title":"ESMO Open"},{"issue":"7","key":"16060_CR42","doi-asserted-by":"publisher","first-page":"e13827","DOI":"10.1111\/jfbc.13827","volume":"45","author":"KA Preethi","year":"2021","unstructured":"Preethi KA, Sekar D. Dietary microRNAs: current status and perspective in food science. J Food Biochem. 2021;45(7):e13827. https:\/\/doi.org\/10.1111\/jfbc.13827.","journal-title":"J Food Biochem"},{"key":"16060_CR43","doi-asserted-by":"publisher","unstructured":"Prinz C, Frese R, Grams M, Fehring L. Emerging Role of microRNA Dysregulation in Diagnosis and Prognosis of Extrahepatic Cholangiocarcinoma. Genes. 2022;13(8). https:\/\/doi.org\/10.3390\/genes13081479.","DOI":"10.3390\/genes13081479"},{"key":"16060_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.placenta.2024.05.135","volume":"153","author":"SC Selvakumar","year":"2024","unstructured":"Selvakumar SC, Sekar D. MicroRNA-510-3p regulated vascular dysfunction in preeclampsia by targeting vascular endothelial growth factor A (VEGFA) and its signalling axis. Placenta. 2024;153:31\u201352. https:\/\/doi.org\/10.1016\/j.placenta.2024.05.135.","journal-title":"Placenta"},{"issue":"1","key":"16060_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-022-10242-x","volume":"22","author":"C Shang","year":"2022","unstructured":"Shang C, Chen Q, Zu F, Ren W. Integrated analysis identified prognostic microRNAs in breast cancer. BMC Cancer. 2022;22(1):1\u201313. https:\/\/doi.org\/10.1186\/s12885-022-10242-x.","journal-title":"BMC Cancer"},{"key":"16060_CR46","doi-asserted-by":"publisher","first-page":"121997","DOI":"10.1016\/j.lfs.2023.121997","volume":"324","author":"X Wang","year":"2023","unstructured":"Wang X, Zhang J, Yu H, Wang Z. Breast cancer heterogeneity: advances and perspectives in molecular mechanisms and treatment strategies. Life Sci. 2023;324:121997. https:\/\/doi.org\/10.1016\/j.lfs.2023.121997.","journal-title":"Life Sci"},{"key":"16060_CR47","doi-asserted-by":"publisher","unstructured":"Yang Z, Liu Z. The Emerging Role of MicroRNAs in Breast Cancer. J Oncol. 2020;2020. https:\/\/doi.org\/10.1155\/2020\/9160905.","DOI":"10.1155\/2020\/9160905"},{"issue":"4","key":"16060_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/bcr2607","volume":"12","author":"EA Rakha","year":"2010","unstructured":"Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12(4):207. https:\/\/doi.org\/10.1186\/bcr2607.","journal-title":"Breast Cancer Res"},{"key":"16060_CR49","doi-asserted-by":"publisher","unstructured":"Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: The St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2021. JNCCN\u2013J Natl Compr Cancer Netw. 2021;19(5):404-417. https:\/\/doi.org\/10.6004\/jnccn.2021.0057.","DOI":"10.6004\/jnccn.2021.0057"},{"key":"16060_CR50","unstructured":"MY Wu, PW Hu, ZH You, J Zhang, L Hu, X Luo. Graph-Based Prediction of miRNA-Drug Associations with Multisource Information and Metapath Enhancement Matrices, in IEEE Journal of Biomedical and Health Informatics. https:\/\/ieeexplore.ieee.org\/document\/10949771"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16060-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16060-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16060-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T23:04:50Z","timestamp":1780873490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16060-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16060"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16060-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were conducted in accordance with the ethical standards of the Declaration of Helsinki. Institutional approval for retrospective human tissue uses and associated clinical data analysis was granted by the Bahawalpur Institute of Nuclear Medicine & Oncology (BINO) Institutional Review Board under approval ID BINO\/IRB\/2024\/1157, covering patient specimens and records collected between January 2018 and December 2023.Written informed consent was obtained from all participants at the time of specimen collection and clinical data recording. All patient identifiers were removed prior to analysis, and anonymization procedures were strictly implemented to maintain data confidentiality. The study adhered to institutional, national, and international guidelines for biomedical research ethics and clinical data governance.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to the publication of this study. Data has been anonymized to protect patient identity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"721"}}